Clopidogrel Tablet
Product Images NDC 67877-276

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 67877-276). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clop02-a (Clop02 A)

A horizontal dot plot graph showing the effect of co-administered proton pump inhibitors (PPIs) — Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, Omeprazole 80 mg — on active metabolite AUC of Clopidogrel (Plavix). The x-axis shows change relative to Plavix administered alone, ranging from 0.4 to 1.4. Each PPI's effect is represented with a mean value and 90% confidence interval.*

FDA Label Image

Clop03-a (Clop03 A)

A line graph comparing cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. Two groups are shown: placebo with aspirin and clopidogrel with aspirin. The clopidogrel group demonstrates consistently lower cumulative event rates throughout the follow-up period. The graph includes a p-value indicating statistical significance.*

FDA Label Image

Clop04-a (Clop04 A)

A forest plot showing hazard ratios with 95% confidence intervals comparing Clopidogrel versus placebo across multiple subgroups based on age, gender, race, cardiac enzyme elevation, diabetes, previous myocardial infarction, stroke, Heparin/LMWH use, aspirin dosage, GPIIb/IIIa antagonist use, beta-blocker use, and ACE inhibitor use. The plot visually indicates whether outcomes favor Clopidogrel or placebo for each subgroup and overall.*

FDA Label Image

Clop08-a (Clop08 A)

A line graph depicting cumulative event rates (%) of fatal or non-fatal vascular events over 36 months of follow-up for aspirin and clopidogrel. The graph shows two lines, with clopidogrel having a slightly lower cumulative event rate than aspirin throughout the period. Statistical significance is noted with P = 0.045.*

FDA Label Image

Clop75-500tabs (Clop75 500tabs)

Clopidogrel Tablets, USP 75 mg oral tablet bottle label by Ascend Laboratories, LLC. Contains 500 tablets. The label includes storage instructions, manufacturer Alkem Laboratories Ltd., barcodes, and dispensing information such as "Rx Only" and advising to dispense the Medication Guide to each patient.*

FDA Label Image

Clop75-90tabs (Clop75 90tabs)

Label for Clopidogrel Tablets USP, 75 mg oral tablets, distributed by Ascend Laboratories, LLC. The label includes the NDC 67877-276-90 and states the product contains clopidogrel bisulfate equivalent to 75 mg clopidogrel base per film-coated tablet. It specifies 90 tablets per container, storage instructions, and directions to dispense the enclosed medication guide.*

FDA Label Image

Clop_01 (Clop 01)

Chemical structure of clopidogrel bisulfate, showing its molecular components including a thiophene ring, a piperidine ring, and a chlorophenyl group with a methyl ester and sulfuric acid as the bisulfate salt.*

FDA Label Image

Clop_05 (Clop 05)

A Kaplan-Meier survival curve displaying percentage of deaths before first discharge over time in days (up to 28) since randomization. The graph compares mortality rates between placebo and Clopidogrel Tablets groups, showing a slight reduction in deaths in the Clopidogrel group (7.5%) versus placebo (8.1%). A 7% proportional risk reduction with a p-value of 0.03 is noted.*

FDA Label Image

Clop_06 (Clop 06)

A line graph comparing the percentage of patients with death, reinfarction, or stroke before first discharge over 28 days between placebo and Clopidogrel tablets. The vertical axis shows the percentage (0-11%), and the horizontal axis marks days since randomization (0-28). The Clopidogrel group shows a lower percentage of events than placebo, indicating a 9% proportional risk reduction (p=0.002).*

FDA Label Image

Clop_07 (Clop 07)

A forest plot showing odds ratios with 95% confidence intervals comparing Clopidogrel tablets to placebo across various subgroups including gender, age at entry, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use. The plot visualizes the relative favorability towards Clopidogrel or placebo for each subgroup and overall.*

FDA Label Image

Clop_09 (Clop 09)

A hazard ratio forest plot comparing Clopidogrel tablets versus Aspirin across qualifying conditions including Stroke, MI, PAD, and Overall. The graph displays numerical data of patients and percentages, with markers indicating favor towards Clopidogrel or Aspirin tablets based on hazard ratios and 95% confidence intervals.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.